<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04251546</url>
  </required_header>
  <id_info>
    <org_study_id>XH-20-002</org_study_id>
    <nct_id>NCT04251546</nct_id>
  </id_info>
  <brief_title>Prediction Model fo Screening and Diagnosis of Prostate Cancer in PSA Gray Zone Based on Serum PHI Combined With TPV</brief_title>
  <official_title>Prediction Model fo Screening and Diagnosis of Prostate Cancer in PSA Gray Zone Based on Serum PHI Combined With TPV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate cancer (PCa) is a high incidence tumor of elderly men. In recent years, its&#xD;
      incidence has rapidly increased in China. Serological examination of prostate-specific&#xD;
      antigen (PSA) is particularly important in the early diagnosis of PCa, but its specificity is&#xD;
      lower in gray areas with PSA between 4-10 ng / ml. Proposition of prostate health index (PHI)&#xD;
      strengthens the specificity of PSA gray area prostate cancer diagnosis, but the composition&#xD;
      of the index only relies on serological examination, neglects imaging indicators, and cannot&#xD;
      be comprehensively evaluated. Based on the preliminary basis of PHI research in the&#xD;
      undergraduate department, combined with ultrasound imaging indicators of total prostate&#xD;
      volume (TPV), this research group prospectively analyzed the efficacy of PHI combined with&#xD;
      TPV to predict prostate cancer in patients with PSA gray areas, and established an improved&#xD;
      version of PHI-TPV combination. The prediction model mPHI assesses the sensitivity of the new&#xD;
      model to predict the risk of prostate cancer in the Chinese population, provides data support&#xD;
      for puncture decisions of middle-aged and elderly male patients in the gray area of PSA in&#xD;
      China, and provides reference and guidance for the individualized prevention and treatment of&#xD;
      prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological confirmed diagnosis of prostate cancer or benign prostatic diseases</measure>
    <time_frame>2019/05/01-2021/05/30</time_frame>
    <description>Pathological confirmed diagnosis by transrectal ultrasound guided prostate biopsy (12 needles) according to a standardized protocol. If a suspicious low-density nodule is found during the ultrasound, biopsy to the nodule can be added. Place the prostate biopsy specimen in a 10% Formalin's specimen bag. The specimens were processed and evaluated by the Pathology Department of Xinhua Hospital.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>PSA</condition>
  <arm_group>
    <arm_group_label>Observational group</arm_group_label>
    <description>Patients with suspected prostate cancer with a PSA test value of 4-10 ng / mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>p2PSA</intervention_name>
    <description>p2PSA test(for calculation of PHI)</description>
    <arm_group_label>Observational group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ultrasonic parameters</intervention_name>
    <description>Ultrasonic parameters(TPV)</description>
    <arm_group_label>Observational group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Transperineal prostate biopsy</intervention_name>
    <description>Transperineal prostate biopsy for confirmation of prostate cancer or benign disease</description>
    <arm_group_label>Observational group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study selected patients with suspected prostate cancer in the Department of Urology,&#xD;
        Xinhua Hospital, Shanghai Jiao Tong University School of Medicine from May 2019 to May&#xD;
        2022, and had a PSA test value of 4-10 ng / mL.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient&gt; 45 years of age&#xD;
&#xD;
          2. Abnormal serum PSA&#xD;
&#xD;
          3. Prostate nodules found by DRE&#xD;
&#xD;
          4. Abnormal MRI or TRUS finding&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Incomplete medical history&#xD;
&#xD;
          2. Poor quality of serum samples&#xD;
&#xD;
          3. Bacterial acute prostatitis diagnosed within 3 months before biopsy 4.5Î± reductase&#xD;
             inhibitors, anabolic steroids, or antiandrogen drugs taken within 12 months before&#xD;
             biopsy&#xD;
&#xD;
        5.Previous prostate biopsy history.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yongjiang Yu, MD.</last_name>
    <phone>86-13916241036</phone>
    <email>yuyongjiang@xinhuamed.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guangyu Chen, MD.</last_name>
      <phone>+86-1356414407</phone>
      <email>chenguangyu@xinhuamed.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 30, 2020</study_first_submitted>
  <study_first_submitted_qc>January 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>October 9, 2021</last_update_submitted>
  <last_update_submitted_qc>October 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>PSA</keyword>
  <keyword>PHI</keyword>
  <keyword>ultrasound</keyword>
  <keyword>TPV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

